Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Dravet Syndrome Companies

ID: MRFR/Pharma/4062-HCR
85 Pages
Vikita Thakur
Last Updated: April 06, 2026

Dravet Syndrome companies specialize in the research and development of therapies and interventions for this rare and severe form of epilepsy. These organizations play a vital role in improving the quality of life for individuals affected by Dravet Syndrome.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Dravet Syndrome Market

Dravet Syndrome Market

 

Latest Dravet Syndrome Companies Updates


Stoke Therapeutics (NASDAQ: STOK): Presented positive data from their Phase 2 open-label extension study of STK-001, an antisense oligonucleotide therapy targeting the SCN1A gene mutation responsible for Dravet Syndrome.


Eisai Inc.: Initiated a Phase 3 clinical trial called Momentum I to study the efficacy of lorcaserin as an adjuctive (add-on) treatment in Dravet Syndrome to reduce seizure frequency.


Encoded Therapeutics: Collaborating with Cook Children's Medical Center on a non-interventional study to identify potential biomarkers for Dravet Syndrome using GABA levels in the blood.


Zogenix Inc.: Partnered with the DSF to provide educational grants to healthcare professionals on the use of Fintepla (fenfluramine) for Dravet Syndrome treatment.


List of Dravet Syndrome Key companies in the market:



  • Biocodex

  • Biscayne Neurotherapeutics

  • Cyberonics

  • Epygenix Therapeutics

  • GW Pharmaceuticals

  • INSYS THERAPEUTICS

  • OPKO Health Inc.

  • Ovid Therapeutics

  • PTC Therapeutics